Radiation safety implications of 131I treatment in a patient with Grave's disease undergoing home hemodialysis.
The radiation safety implications following the administration of 131I for the treatment of Grave's disease to a patient undergoing home-based renal dialysis was investigated. External dose-rate measurements from the patient revealed a peak value at around day 2, post administration. The effective half-life was determined as 6.5 d. From day 3, the clearance of 131I was observed to be fairly constant and equated to 2.7% per day or 5.4% per dialysis session. From this the biological half-life was determined as 15 d. Radiation monitoring of the dialysis unit, disposables, and bed linen found no detectable contamination. For the purpose of useful protection, at a distance of 1 m from the patient, the average dose rate over the effective treatment duration was determined to be 8 microSv h(-1) and at 2 m distance, 2.6 microSv h(-1). Thus, in order to keep below a level of dose constraint of 3 mSv the total allowable time spent at 1 m would be 375 h or 15 h per day. To comply with a 1-mSv constraint, the average daily exposure allowable at 1 m would be 5 h per day. Neither of these time limits would be difficult to achieve for the majority of situations with fairly modest behavioral constraints. Initial discharge concentration rates into the waste water system are estimated at 200 MBq m(-3) and therefore might need to be considered depending upon the regulatory environment.
Simpson
J B
JB
Department of Medical Physics, The Townsville Hospital, Townsville, Australia. john_simpson@health.qld.gov.au
Godwin
G A
GA
D005260:Female; D006111:Graves Disease / Q000150:complications / Q000532:radiotherapy*; D006437:Hemodialysis, Home; D006801:Humans; D007457:Iodine Radioisotopes; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D011829:Radiation Dosage; D011835:Radiation Protection
D007457:Iodine Radioisotopes